Antipsychotics for the treatment of Behavioral and Psychological Symptoms of Dementia (BPSD)

Current Neuropharmacology

Volumn 6, Issue 2, 2008, Pages 117-124

  Liperoti, Rosa ^a,e   Pedone, Claudio ^b   Corsonello, Andrea ^c,d  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c Fondazione San Raffaele   (Italy)

^d INRCA   (Italy)

^e NONE   (Italy)

Author keywords

Antipsychotics; Behavioral and psychological symptoms of dementia (BPSD); Dementia

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUTYROPHENONE DERIVATIVE; CHOLINESTERASE INHIBITOR; CLOZAPINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; PLACEBO; QUETIAPINE; RACLOPRIDE; RISPERIDONE; RIVASTIGMINE; SULPIRIDE; THIORIDAZINE; THIOXANTHENE DERIVATIVE; ZIPRASIDONE;

AGITATION; ALZHEIMER DISEASE; BEHAVIOR DISORDER; CARDIOTOXICITY; CAREGIVER BURDEN; CLINICAL TRIAL; DELUSION; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; INSTITUTIONALIZATION; MENTAL DISEASE; METABOLIC DISORDER; MORTALITY; NEUROPHARMACOLOGY; PARKINSONISM; PATHOPHYSIOLOGY; PREVALENCE; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SLEEP DISORDER; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; VERBAL HOSTILITY; WANDERING BEHAVIOR; WEIGHT GAIN;

EID: 47749146154     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015908784533860     Document Type: Review

References (90)

1. Alexopoulos, G.S., Jeste, D.V., Chung, H., Carpenter, D., Ross, R., Docherty, J.P. (2005) The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary. Postgrad. Med., Spec No, 6-22.
2. American Geriatrics Society and American Association for Geriatric Psychiatry. (2003) Consensus statement on improving the quality of mental health care in US nursing homes: management of depression and behavioral symptoms associated with dementia. J. Am. Geriatr. Soc., 51, 1287-1298.
3. Baldessarini, R.J., Frankenburg, F.R. (1991) Clozapine. A novel antipsychotic agent. N. Engl. J. Med., 324, 746-754.
4. Ballard, C., Margallo-Lana, M., Juszczak, E., Douglas, S., Swann, A., Thomas, A., O'Brien, J., Everratt, A., Sadler, S., Maddison, C., Lee, L., Bannister, C., Elvish, R., Jacoby, R. (2005) Quetiapine and r ivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ, 330, 874.
5. Ballard, C., Waite, J. (2006) The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst. Rev., 1, CD003476.
6. Barnes, R., Veith, R., Okimoto, J., Raskind, M., Gumbrecht, G. (1982) Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am. J. Psychiatry, 139, 1170-1174.
7. Benoit, M., Arbus, C., Blanchard, F., Camus, V., Cerase, V., Clement, J.P., Fremont, P., Guerin, O., Hazif, T.C., Jeanblanc, F., Lafont, C., Moreaud, O., Pedra, M., Poncet, M., Richard, H.S., Rigaud, A.S., Sotto, M.M.E., Touchon, J., Vellas, B., Fitten, L.J., Robert, P.H. (2006) Professional consensus on the treatment of agitation, aggressive behaviour, oppositional behaviour and psychotic disturbances in dementia. J. Nutr. Health Aging, 10, 410-415.
8. Benoit, M., Brocker, P., Clement, J.P., Cnockaert, X., Hinault, P., Nourashemi, F., Pancrazi, M.P., Portet, F., Robert, P., Thomas, P., Verny, M., Groupe de consensus Théma. (2005) Behavioral and psychological symptoms in dementia: description and management. Rev. Neurol (Paris), 161, 357-366.
9. Benoit, M., Robert, P.H., Staccini, P., Brocker, P., Guerin, O., Lechowski, L., Vellas, B., REAL FR Group. (2005) One-year longitudinal evaluation of neuropsychiatric symptoms in Alzheimer's disease. The REAL.FR Study. J. Nutr. Health Aging, 9, 95-99.
10. Benoit M., Staccini, P., Brocker, P., Benhamidat, T,, Bertogliati, C., Lechowski, L., Tortrat, D., Robert, P.H. (2003) Behavioral and psychologic symptoms in Alzheimer's disease: results of the REAL.FR study. Rev. Med. Int., 24, 319s-324s.
11. Bozeat, S., Gregory, C.A., Ralph, M.A., Hodges, J.R. (2000) Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease? J. Neurol. Neurosurg. Psychiatry, 69, 178-186.
12. Braak, H., Braak, E. (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol., V82, 239-259.
13. Brodaty, H., Ames, D., Snowdon, J., Woodward, M., Kirwan, J., Clarnette, R., Lee, E., Lyons, B., Grossman, F. (2003) A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J. Clin. Psychiatry, 64, 134-143.
14. Buhr, G.T., White, H.K. (2006) Difficult behaviors in long-term care patients with dementia. J. Am. Med. Dir. Assoc., 7, 180-192.
15. Burris, K.D., Molski, T.F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F.D., Molinoff P.B. (2002) Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors. J. Pharmacol. Exp. Ther., 302, 381-389.
16. Chan, D.C., Kasper, J.D., Black, B.S., Rabins, P.V. (2003) Prevalence and correlates of behavioral and psychiatric symptoms in community-dwelling elders with dementia or mild cognitive impairment: the Memory and Medical Care Study. Int. J. Geriatr. Psychiatry, 18, 174-182.
17. Cohen, C.A., Gold, D.P., Shulman, K.I., Wortley, J.T., McDonald, G., Wargon, M. (1993) Factors determining the decision to institutionalize dementing individuals: a prospective study. Gerontologist, 33, 714-720.
18. Cohen-Mansfield, J., Billig, N. (1998) Agitated behaviours in the elderly. I: a conceptual review. J. Am. Geriatr. Soc., 36, 7-12.
19. Collaborative Working Group on Clinical Trial Evaluations. (1998) Treatment of special populations with the atypical antipsychotics. J. Clin. Psychiatr., 59(suppl 12), 46-52.
20. Cummings, J.L., Diaz, C., Levy, M. (1996) Behavioral syndromes in neurodegenerative diseases: frequency and significance. Semin. Neuropsychiatry, 1, 241-247.
21. De Deyn, P., Jeste, D.V., Swanink, R., Kostic, D., Breder, C., Carson, W.H., Iwamoto, T. (2005) Axipiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J. Clin. Psychopharmacol., 25, 463-467.
22. De Deyn, P.P., Carrasco, M.M., Deberdt, W., Jeandel, C., Hay, D.P., Feldman, P.D., Young, C.A., Lehman, D.L., Breier, A. (2004) Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry, 19, 115-126.
23. De Deyn, P.P., Rabheru, K., Rasmussen, A., Bocksberger, J.P., Dautzenberg, P.L., Eriksson, S., Lawlor, B.A. (1999) A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology, 53, 946-955.
24. Deberdt, W.G., Dysken, M.W., Rappaport, S.A., Feldman, P.D., Young, C.A., Hay, D.P., Lehman, D.L., Dossenbach, M., Degenhardt, E.K., Breier, A. (2005) Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am. J. Geriatr. Psychiatry, 13, 722-730.
25. Eustace, A., Coen, R., Walsh, C., Cunningham, C.I., Walsh, J.B., Coakley, D., Lawlor, B.A. (2002) A longitudinal evaluation of behavioural and psychological symptoms of probable Alzheimer's disease. Int. J. Geriatr. Psychiatry, 17, 968-973.
26. Eustace, A., Kidd, N., Greene, E., Fallon, C., Bhrain, S.N., Cunningham, C., Coen, R., Walsh, J.B., Coakley, D., Lawlor, B.A. (2001) Verbal aggression in Alzheimer's disease. Clinical, functional and neuropsychological correlates. Int. J. Geriatr. Psychiatry, 16, 858-861.
27. Expert Consensus Panel for Dementia. (2005) The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Postgrad Med., Spec No, 1-111.
28. Factor, S.A. (2002) Pharmacology of atypical antipsychotics. Clin. Neuropharmacol., 25, 153-157.
29. Farber, N.B., Rubin, E.H., Newcomer, J.W., Kinscherf, D.A., Miller, J.P., Morris, J.C., Olney, J.W., McKeel, D.W. Jr. (2000) Increased nericortical neurofibrillary tangle density in subjects with alzheimer disease and psychosis. Arch. Gen. Psychiatry, 57, 1165-1173.
30. Farde, L., Nordstrom, A.L., Wiesel, F.A., Pauli, S., Halldin, C., Sedvall, G. (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry, 49, 538-544.
31. FDA Public Health Advisory. (2005) Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Available at http:/www.fda.gov/ oder/drug/advisory/antipsychotics.htm (accessed April 11, 2005).
32. Fischman, A.J., Bonab, A.A., Babich, J.W., Alpert, N.M., Rauch, S.L., Elmaleh, D.R., Shoup, T.M., Williams, S.A., Rubin, R.H. (1996) Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J. Pharmacol. Exp. Ther., 279, 939-947.
33. Fitten, L.J. (2006) Management of behavioral and psychiatric symptoms of dementia. J. Nutr. Health Aging, 10, 409.
34. Forstl, H., Burns, A., Levy, R., Cairns, N. (1994) Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease. Br. J. Psychiatry, 165, 53-59.
35. Gerlach, J. (2000) Atypical antipsychotics: an inspiring but confusing concept. Psychopharmacology, 148, 1-2.
36. Gill, S.S., Rochon, P.A., Herrmann, N., Lee, P.E., Sykora, K., Gunraj, N., Normand, S.L., Gurwitz, J.H., Marras, C., Wodchis, W.P., Mamdani, M. (2005) Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ, 330, 445.
37. Glick, I.D., Murray, S.R., Vasudevan, P., Marder, S.R., Hu, R.J. (2001) Treatment with atypical antipsychotics: new indications and new populations. J. Psychiatr. Res., 35, 197-191.
38. Harding, A.J., Broc, G.A., Halliday, G.M. (2002) Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain, 125, 391-403.
39. Harvey, R.J., Ellison, D., Hardy, J., Hutton, M., Roques, P.K., Collinge, J., Fox, N.C., Rossor, M.N. (1998) Chromosome 14 familial Alzheimer's disease: the clinical and neuropathological characteristics of a family with a leucine-serine (L250S) substitution at codon 250 of the presenilin lágene. J. Neurol. Neurosurg. Psychiatry, 64, 44-49.
40. Hennessy, S., Bilker, W.B., Knauss, J.S., Margolis, D.J., Kimmel, S.E., Reynolds, R.F., Glasser, D.B., Morrison, M.F., Strom, B.L. (2002) Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ, 325, 1070-1074.
41. Herrmann, N., Lanctot, K.L. (2005) Do atypical antipsychotics cause stroke? CNS Drugs, 19, 91-103.
42. Herrmann, N., Mamdani, M., Lanctot, K.L. (2004) Atypical antipsychotics and risk of cerebrovascular accidents. Am. J. Psychiatry, 161, 1113-1115.
43. Hirono, N., Mega, M.S., Dinov, I.D., Mishkin, F., Cummings, J.L. (2000) Left frontotemporal hypoperfusion is associated with aggression in patients with dementia. Arch. Neurol., 57, 861-866.
44. Holmes, C., Arranz, M.J., Powell, J.F., Collier, D.A., Lovestone, S. (1998) 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum. Mol. Genet., 7, 1507-1509.
45. Holtzer, R., Tang, M.X., Devanand, D.P., Albert, S.M., Wegesin, D.J., Marder, K., Bell, K., Albert, M., Brandt, J., Stern, Y. (2003) Psychopathological features in Alzheimer's disease: course and relationship with cognitive status. J. Am. Geriatr. Soc., 51, 953-960.
46. Jibson, M.D., Tandon, R. (1998) New atypical antipsychotic medications. J. Psychiat. Res., 32, 215-228.
47. Jost, B.C., Grossberg, G.T. (1996) The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J. Am. Geriatr. Soc., 44, 1078-1081.
48. Kapur, S., Remington, G., Zipursky, R.B., Wilson, A.A., Houle, S. (1995) The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci., 57, L103-L107.
49. Kapur, S., Seeman, P. (2001) Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis. Am. J. Psychiatry, 158, 360-369.
50. Kapur, S., Zipursky, R., Jones, C., Remington, G., Houle, S. (2000) Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind pet study of first-episode schizophrenia. Am. J. Psychiatry, 157, 514-520.
51. Kapur, S., Zipursky, R.B., Remington, G. (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry, 156, 286-293.
52. Katz, I.R., Jeste, D.V., Mintzer, J.E., Clyde, C., Napolitano, J., Brecher, M. (1999) Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J. Clin. Psychiatry, 60, 107-115.
53. Kurlan, R., Cummings, J., Raman, R., Thal, L., for the Alzheimer's Disease Cooperative Study Group. (2007) Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology, 68, 1356-1363.
54. Levy, M.L., Cummings, J.L., Fairbanks, L.A., Bravi, D., Calvani, M., Carta, A. (1996) Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am. J. Psychiatry, 153, 1438-1443.
55. Levy, M.L., Miller, B.L., Cummings, J.L., Fairbanks, L.A., Craig, A. (1996) Alzheimer disease and frontotemporal dementias. Behavioral distinctions. Arch. Neurol., 53, 687-690.
56. Lidsky, T.I., Yablonsky-Alter, E., Zuck, L., Banerjee, S.P. (1993) Anti-glutamatergic effects of clozapine. Neurosci. Lett., 163, 155-158.
57. Liperoti, R., Gambassi, G., Lapane, K.L., Chiang, C., Pedone, C., Mor, V., Bernabei, R. (2005) Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J. Clin. Psychiatry, 66, 1090-1096.
58. Liperoti, R., Gambassi, G., Lapane, K.L., Chiang, C., Pedone, C., Mor, V., Bernabei, R. (2005) Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Arch. Int. Med., 165, 696-701.
59. Liperofi, R., Mor, V., Lapane, K.L., Pedone, C., Gambassi, G., Bernabei, R. (2003) The use of atypical antipsychotics in nursing home. J. Clin. Psychiatry, 64, 1106-1112.
60. Lonergan, E., Luxerberg, J., Colford, J. (2002) Haloperidol for agitation in dementia. Cochrane Database Syst. Rev., 2, CD002852.
61. Lopez, O.L., Smith, G., Becker, J.T., Meltzer, C.C., DeKosky, S.T. (2001) The psychotic phenomenon in probable Alzheimer's disease: a positron emission tomography study. J. Neuropsychiat. Clin. Neurosci., 13, 50-55.
62. Lyketsos, C.G., Lopez, O., Jones, B., Fitzpatrick, A.L., Breitner, J., DeKosky, S. (2002) Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA, 288, 1475-1483.
63. Lyketsos, C.G., Steinberg, M., Tschanz, J.T., Norton, M.C., Steffens, D.C., Breitner, J.C. (2000) Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am. J. Psychiatry, 157, 708-714.
64. McKeith, I., Cummings, J. (2005) Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol., 4, 735-742.
65. Meins, W., Frey, A., Thiesemann, R. (1998) Premorbid personality traits in Alzheimer's disease: do they predispose to noncognitive behavioral symptoms? Int. Psychogeriatr., 10, 369-378.
66. Melkersson, K., Dahl, M.L. (2004) Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugsy 64, 701-723.
67. Meltzer, H.Y., Matsubara, S., Lee, J.C. (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther., 251, 238-246.
68. Mossman, D., Lehrer, D.S. (2000) Conventional and atypical antipsychotics and the evolving standard of care. Psychiatr. Serv., 51, 1528-1535.
69. Neary, D., Snowden, J.S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P.H., Albert, M., Boone, K., Miller, B.L., Cummings, J., Benson, D.F. (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology, 51, 1546-1554.
70. Nordström, A.L., Farde, L., Wiesel, F.A., Forslund, K., Pauli, S., Halldin, C., Uppfeldt, G. (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol. Psychiatr., 33, 227-235.
71. Ray, W.A., Meredith, S., Thapa, P.B., Meador, K.G., Hall, K., Murray, K.T. (2001) Antipsychotics and the risk of sudden cardiac death. Arch. Gen. Psychiatry, 58, 1161-1167.
72. Richelson, E. (1996) Preclinical pharmacology of neuroleptics: focus on new generation compounds. J. Clin. Psychiatry, 57(Suppl. 11), 4-11.
73. Scarmeas, N., Brandt, J., Albert, M., Hadjigeorgiou, G., Papadimitriou, A., Dubois, B., Sarazin, M., Devanand, D., Honig, L., Marder, K., Bell, K., Wegesin, D., Blacker, D., Stern, Y. (2005) Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch. Neurol., 62, 1601-1608.
74. Schneider, L.S., Dagerman, K.S., Insel, P. (2005) Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA, 294, 1934-1943,
75. Schneider, L.S., Pollock, V.E., Lyness, S.A. (1990) A metaanalysis of controlled trials of neuroleptic, treatment in dementia. J. Am. Geriatr. Soc., 38, 553-563.
76. Schneider, L.S., Tariot, P.N., Dagerman, K.S., Davis, S.M., Hsiao, J.K., Ismail, M.S., Lebowitz, B.D., Lyketsos, C.G., Ryan, J.M., Stroup, T.S., Sultzer, D.L., Weintraub, D., Lieberman, J.A. CATIE-AD Study Group. (2006) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N. Engl. J. Med., 355, 1525-1538.
77. Schoemaker, H., Claustre, Y., Fage, D., Rouquier, L., Chergui, K., Curer, O., Oblin, A., Gonon, F., Carter, C., Benavides, J., Scatton, B. (1997) Neurochemical Characteristics of Amisulpride, an Atypical Dopamine D2/D3 Receptor Antagonist with Both Presynaptic and Limbic Selectivity. J. Pharmacol. Exp. Ther., 280, 83-97.
78. Straus, S.M., Bleumink, G.S., Dieleman, J.P., van der Lei, J., 't Jong, G.W., Kingma, J.H., Sturkenboom, M.C., Stricker, B.H. (2004) Antipsychotics and the risk of sudden cardiac death. Arch. Int. Med., 164, 1293-1297.
79. Strauss, M.E., Lee, M.M., DiFilippo, J.M. (1997) Premorbid personality and behavioral symptoms in Alzheimer disease. Some cautions. Arch. Neurol., 54, 257-259.
80. Street, J.S., Clark, W.S., Gannon, K.S., Cummings, J.L., Bymaster, F.P., Tamura, R.N., Mitan, S.J., Kadam, D.L., Sanger, T.M., Feldman, P.D., Tollefson, G.D., Breier, A. (2000) Olarizapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch. Gen. Psychiatry, 57, 968-976.
81. Sukonick, D.L., Pollock, B.G., Sweet, R.A., Mulsant, B.H., Rosen, J., Munk, W.E., Kastango, K.B., DeKosky, S.T., Ferrell, R.E. (2001) The 5-HTTPR*S/*L Polymorphism and Aggressive Behavior in Alzheimer Disease. Arch. Neurol., 58, 1425-1428.
82. Sultzer, D.L., Brown, C.V., Mandelkern, M.A., Mahler, M.E., Mendez, M.F., Chen, S.T., Cummings, J.L. (2003) Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease. Am. J. Psychiatry, 160, 341-349.
83. Sweet, R.A., Nimgaonkar, V.L., Kamboh, M.I., Lopez, O.L., Zhang, F., DeKosky, S.T. (1998) Dopamine Receptor Genetic Variation, Psychosis, and Aggression in Alzheimer Disease. Arch. Neurol., 55, 1335-1340.
84. Sweet, R.A., Pollock, B.G., Sukonick, D.L., Mulsant, B.H., Rosen, J., Klunk, W.E., Kastango, K.B., DeKosky, S.T., Ferrell, R.E. (2001) The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease. Int. J. Psychogeriatr., 13, 401-409.
85. Tekin, S., Mega, M.S., Masterman, D.M., Chow, T., Garakian, J., Vinters, H.V., Cummings, J.L. (2001) Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann. Neurol., 49, 355-361.
86. Wang, P.S., Schneeweiss, S., Avorn, J., Fischer, M.A., Mogun, H., Solomon, D.H., Brookhart, M.A. (2005) Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N. Engl. J. Med., 353, 2335-2341.
87. Wooltorton, E. (2004) Olanzapine (Zyprexa): increased rate of cerebrovascular events in dementia trials. CMAJ, 170, 1395.
88. Wooltorton, E. (2002) Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CAMJ, 167, 1269-1270.
89. Xiberas, X., Martinot, J.L., Mallet, L., Artiges, E., Loc'H, C., Mazière, B., Paillère-Martinot, M.L. (2001) Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br. J. Psychiatry, 179, 503-508.
90. Zhong, K.X., Tariot, P.N., Mintzer, J., Minkwitz, M.C., Devine, N.A. (2007) Quetiapine to treat agitation in dementia: a randomized double-blind, placebo-controlled study. Curr. Alzheimer Res., 4, 81-93.